Allogene Therapeutics Inc
ALLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$519.44M
Close$
$-0.14
106.9% downside
Current Fair Value
106.9% downsideOvervalued by 106.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $519.44 Million |
|---|---|
| Enterprise Value | $642.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.87 |
| Beta | 0.46 |
| Outstanding Shares | 240,290,782 |
Return
| Return on Equity | -62.31% |
|---|---|
| Return on Assets | -43.88% |
| Return on Invested Capital | -55.98% |
Valuation & Multiples
| P/E Ratio | -2.77 |
|---|---|
| PEG | 9.65 |
| Price to Sales | - |
| Price to Book Ratio | 2.08 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.12 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$2,222
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$2,222
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4438▲ 28.84% |
|---|---|
| Total Calls | 279,600▲ 46.31% |
| Total Puts | 124,100▲ 317.85% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.47%▲ 10.22% |
|---|---|
| Total Invested | $444.66M▲ 99.64% |
| Investors Holding | 213▲ 37.00% |
ESG Score
No data